Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event

An Observational Study Into the Usage and Efficacy of Crestor 5mg as a Start Dosage in Achieving the LDL-C Target Level in Both Statin-naive and Treated Primary and Secondary Prevention Patients With a High Risk of a Cardiovascular Event.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00347217

Enrollment

3840

Registered

2006-07-04

Start date

2006-02-28

Completion date

2009-01-31

Last updated

2011-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesteremia

Keywords

Cholesterol, rosuvastatin, LDL-C goal, observational study, primary prevention, secondary prevention

Brief summary

Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* The patient has a high risk of a cardiovascular event as defined by the European guidelines. * The patient is statin-naive (i.e. has not used a statin \> 2 months), or is currently treated with atorvastatin, pravastatin or simvastatin. * An LDL-C level is known for the statin-naive patient or for the statin used during visit 1. * It has been decided to start the patient on CRESTOR 5 mg. * The patient is prepared to give permission to the coded data being made available to AstraZeneca

Exclusion criteria

* The patient is known to have complaints of myalgia, myopathy or liver function impairment (including elevated levels of serum transaminases) where there is a causal relationship with the statin treatment. * Contraindications for treatment with CRESTOR (see 1 B1 text). * Patients with a family history of dyslipidemias, for instance familiar (combined) hypercholesterolemia

Countries

Netherlands

Outcome results